Prognostic Value of 18F-FDG PET-CT Metabolic Index for Nasopharyngeal Carcinoma

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2009 Nov 26

PMID 19936788

Citations 40

Authors

Peng Xie

Jin-Bo Yue

Han-Xi Zhao

Xin-Dong Sun

Li Kong

Zheng Fu

Jin-Ming Yu

Affiliations

Soon will be listed here.

Abstract

Purpose: The purpose of this study was to evaluate the prognostic value of metabolic tumor volume (MTV) and metabolic index (MI) from fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) in patients with nasopharyngeal carcinoma (NPC).

Methods: From October 2002 to July 2004, 41 patients with NPC who underwent (18)F-FDG PET-CT scan before and after radiotherapy were reviewed retrospectively. All patients received intensity-modulated radiotherapy using 6MV X-rays. We examined the association of MTV and the results of long-term follow-up of the patients.

Results: Patients having tumors with an MTV below 30 cm(3) had significantly better 5-year overall survival (OS) (84.6:46.7%, P = 0.006) and disease-free survival (DFS) (73.1:40.0%, P = 0.014) than patients with an MTV of 30 cm(3) or greater. And the patients with MI below 130 had significantly higher 5-year OS (88.0:43.8%, P = 0.002) and DFS (76.0:37.5%, P = 0.005) than other patients. In the Cox multivariate analysis, MI and metabolic response (MR) were predictive of DFS, and we did not find a significant relationship between standard uptake value (SUV) and OS or DFS.

Conclusions: The present study shows that tumor volume parameters, especially the combination of MTV and SUV in the "metabolic index", are valuable for predicting long-term survival. High MI may be useful for identifying patients requiring more aggressive treatment.

Citing Articles

Predictive value of metabolic parameters and apparent diffusion coefficient derived from 18F-FDG PET/MR in patients with non-small cell lung cancer.

Jiang H, Li Z, Meng N, Luo Y, Feng P, Fu F BMC Med Imaging. 2024; 24(1):290.

PMID: 39472782 PMC: 11523797. DOI: 10.1186/s12880-024-01445-8.

PET/CT standardized uptake value and EGFR expression predicts treatment failure in nasopharyngeal carcinoma.

Fei Z, Xu T, Hong H, Xu Y, Chen J, Qiu X Radiat Oncol. 2023; 18(1):33.

PMID: 36814303 PMC: 9945369. DOI: 10.1186/s13014-023-02231-6.

Focal Nasopharyngeal Activity Detected on [F]FDG PET/CT: Clinical Implications and Comparison of Metabolic Parameters for Prediction of Malignancy.

Wong W Nucl Med Mol Imaging. 2022; 56(6):299-305.

PMID: 36425278 PMC: 9679055. DOI: 10.1007/s13139-022-00771-5.

M1 stage subdivisions based on F-FDG PET-CT parameters to identify locoregional radiotherapy for metastatic nasopharyngeal carcinoma.

Qiu H, Zhang X, Liu S, Sun X, Mo Y, Lin H Ther Adv Med Oncol. 2022; 14:17588359221118785.

PMID: 35983026 PMC: 9379565. DOI: 10.1177/17588359221118785.

Pretreatment [F]FDG PET/CT and MRI in the prognosis of nasopharyngeal carcinoma.

Gihbid A, Cherkaoui Salhi G, Alami I, Belgadir H, Tawfiq N, Bendahou K Ann Nucl Med. 2022; 36(10):876-886.

PMID: 35836088 DOI: 10.1007/s12149-022-01770-4.

References

Nakao K, Mochiki M, Nibu K, Sugasawa M, Uozaki H . Analysis of prognostic factors of nasopharyngeal carcinoma: impact of in situ hybridization for Epstein-Barr virus encoded small RNA 1. Otolaryngol Head Neck Surg. 2006; 134(4):639-45. DOI: 10.1016/j.otohns.2005.11.022. View

Lordick F, Ott K, Krause B, Weber W, Becker K, Stein H . PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007; 8(9):797-805. DOI: 10.1016/S1470-2045(07)70244-9. View

Allal A, Slosman D, Kebdani T, Allaoua M, Lehmann W, Dulguerov P . Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys. 2004; 59(5):1295-300. DOI: 10.1016/j.ijrobp.2003.12.039. View

Huang S . Anatomy of SUV. Standardized uptake value. Nucl Med Biol. 2000; 27(7):643-6. DOI: 10.1016/s0969-8051(00)00155-4. View

Cheson B, Pfistner B, Juweid M, Gascoyne R, Specht L, Horning S . Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25(5):579-86. DOI: 10.1200/JCO.2006.09.2403. View

Spiro S, Buscombe J, Cook G, Eisen T, Gleeson F, OBrien M . Ensuring the right PET scan for the right patient. Lung Cancer. 2007; 59(1):48-56. DOI: 10.1016/j.lungcan.2007.07.026. View

La T, Filion E, Turnbull B, Chu J, Lee P, Nguyen K . Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009; 74(5):1335-41. PMC: 2752334. DOI: 10.1016/j.ijrobp.2008.10.060. View

van Tinteren H, Hoekstra O, Smit E, van den Bergh J, Schreurs A, Stallaert R . Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet. 2002; 359(9315):1388-93. DOI: 10.1016/s0140-6736(02)08352-6. View

Cunningham D, Allum W, Stenning S, Thompson J, van de Velde C, Nicolson M . Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355(1):11-20. DOI: 10.1056/NEJMoa055531. View

10.

Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K . [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 2005; 23(6):1136-43. DOI: 10.1200/JCO.2005.06.129. View

11.

Lee S, Nam S, Im K, Kim J, Choi E, Ahn S . Prediction of prognosis using standardized uptake value of 2-[(18)F] fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas. Radiother Oncol. 2008; 87(2):211-6. DOI: 10.1016/j.radonc.2008.01.009. View

12.

Yeh S, Tang Y, Lui C, Huang Y, Huang E . Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone. Int J Radiat Oncol Biol Phys. 2005; 62(3):672-9. DOI: 10.1016/j.ijrobp.2004.11.002. View

13.

Wang L, Chai C, Kuo W, Tai C, Lee K, Ho K . Correlation between proliferating cell nuclear antigen and p53 protein expression and 5-year survival rate in nasopharyngeal carcinoma. Am J Otolaryngol. 2006; 27(2):101-5. DOI: 10.1016/j.amjoto.2005.07.018. View

14.

Nahmias C, Hanna W, Wahl L, Long M, Hubner K, Townsend D . Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT. J Nucl Med. 2007; 48(5):744-51. DOI: 10.2967/jnumed.106.038513. View

15.

Xu X, Yu J, Sun X, Yang G, Li K, Fu Z . The prognostic value of 18F-fluorodeoxyglucose uptake by using serial positron emission tomography and computed tomography in patients with stage III nonsmall cell lung cancer. Am J Clin Oncol. 2008; 31(5):470-5. DOI: 10.1097/COC.0b013e31816fc943. View

16.

Lee P, Weerasuriya D, Lavori P, Quon A, Hara W, Maxim P . Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys. 2007; 69(2):328-33. DOI: 10.1016/j.ijrobp.2007.04.036. View

17.

Lin C, Itti E, Haioun C, Petegnief Y, Luciani A, Dupuis J . Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007; 48(10):1626-32. DOI: 10.2967/jnumed.107.042093. View

18.

Greven K, Williams 3rd D, McGuirt Sr W, Harkness B, DAgostino Jr R, Keyes Jr J . Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck. 2002; 23(11):942-6. DOI: 10.1002/hed.1136. View

19.

Wieder H, Beer A, Lordick F, Ott K, Fischer M, Rummeny E . Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. J Nucl Med. 2005; 46(12):2029-34. View

20.

Swisher S, Maish M, Erasmus J, Correa A, Ajani J, Bresalier R . Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg. 2004; 78(4):1152-60. DOI: 10.1016/j.athoracsur.2004.04.046. View